Bruker Daltonics and Leiden University Medical Center Announce Biomarker Discovery and Clinical Proteomics Collaboration.

Business Editors

BILLERICA, Mass. & LEIDEN, The Netherlands--(BUSINESS WIRE)--Dec. 4, 2003

Bruker Daltonics Inc., an operating company of Bruker BioSciences Corp. (NASDAQ: BRKR) and the Leiden University Medical Center (LUMC) today announced an advanced research collaboration on biomarker discovery and clinical proteomics. Building on the success of an earlier collaboration, the LUMC has acquired four new mass spectrometry systems, as well as clinical proteomics sample preparation and bioinformatics solutions, from Bruker Daltonics. The LUMC will provide feedback on instrumentation, methods and software development for clinical research to Bruker Daltonics.

Professor Dr. Andre M. Deelder, Program Leader in the LUMC Department of Parasitology, explained: "As an extension of our already on-going collaboration with Bruker Daltonics, our (glyco-) proteomics group will be using a new esquire HCT high capacity ion trap mass spectrometer for glycan analysis. Another HCT ion trap will be used for proteomics work in general. We have had a high degree of success with our Ultraflex TOF/TOF mass spectrometer, and are now adding a second one. In addition, we will be installing an Apex-Q 9.4 Tesla hybrid Q-q-FTMS system incorporating the practical ESI/MALDI Combisource, and a ECD/IRMPD accessory for post-translational modification studies. The APEX-Q and the second Ultraflex TOF/TOF will be used for clinical proteomics and glycoprotein research. Our group really values the high quality support and service we have received from Bruker Daltonics' applications laboratories in Europe."

Dr. Rob Tollenaar, Principal Investigator in the Department of Surgery's translational research project, added: "We will use this highly advanced mass spectrometry platform within the framework of our comprehensive diagnostic and prognostic biomarker research program for the analysis of serum and tissue samples. Our research is focused on the improvement of surgical cancer treatment, especially for colorectal, breast and gastric cancer, as well as cancer diagnosis. The department performs clinical research in phase I, II, and III studies, and laboratory research, including research in animal models. This novel mass spectrometry instrumentation will play an important role in clinical research here at LUMC."

Frank Laukien, Ph.D., President and CEO of Bruker Daltonics stated: "Research scientists and clinicians see our ClinProt(TM) clinical proteomics system as a very powerful tool for biomarker discovery and the development of clinical proteomics assays. Our MALDI-TOF and TOF/TOF systems already have become an important molecular diagnostics research platform for peptide and protein biomarker panels that need the multi-channel measurement advantage of mass spectrometry. Now, our ClinProt automation and bioinformatics solution can also integrate ultra-high resolution LC/FTMS."

He continued: "We are very pleased to be working with leading proteomics scientists and clinicians like Professor Deelder and Dr. Tollenaar in this rapidly developing field of clinical proteomics. It is our privilege to have excellent relations with the Dutch scientific and clinical research community. Earlier, our first APEX-Q in Europe was acquired by the University of Amsterdam in a proteomics research collaboration, and now LUMC has placed the largest mass spectrometry order which we have ever received in The Netherlands for utilizing high-field hybrid FTMS, TOF/TOF and ion traps for clinical proteomics research."

ABOUT THE LEIDEN UNIVERSITY MEDICAL CENTER

The Leiden University Medical Center is one of several academic medical centers in the Netherlands. The core tasks of the LUMC are patient care (routine care, high-level clinical care, and in particular, high-level reference care); research (both fundamental and bedside, healthcare-oriented research); education in medicine and biomedical sciences; specialist medical training; and additional training, both post-doctoral and post-vocational. The LUMC comprises the Leiden University Hospital and the Faculty of Medicine of Leiden University. The LUMC employs approximately 7000 people. For further information, please visit http://www.lumc.nl/english/general/aboutLUMC.html

ABOUT BRUKER BIOSCIENCES

Bruker BioSciences, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. For more information about Bruker BioSciences Corporation, please visit www.bruker-biosciences.com

CAUTIONARY STATEMENT OF BRUKER BIOSCIENCES

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the companies' reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the companies' products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2002, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements.